Bringing the Malaysian healthcare industry to greater heights: Provepharm and Pharm-D join forces to provide “Proveblue® 5 mg/ml solution for injection” in Malaysia
France and Malaysia, August 8th, 2023
Provepharm, an international, private and sustainable pharmaceutical company specialized in revitalizing molecules and Pharm-D, a healthcare and pharmaceutical company based in Malaysia with a strong foothold in Singapore, announce today their partnership to launch Proveblue® 5 mg/ml solution for injection in Malaysia. Proveblue ® is, a methylthioninium chloride product compliant with European Pharmacopeia standards.
Proveblue® 5 mg/ml solution for injection is indicated in Malaysia for the treatment of drug and chemical products-induced methaemoglobinaemia, as a dye in diagnostic procedures such as fistula detection and for the delineation of certain body tissues during surgery.
Marketing authorization of Proveblue® 5mg/ml, solution for injection was granted by the Malaysian authorities in January 2023. It is the only methylthioninium chloride product registered in Malaysia.
Under this agreement, Pharm-D is responsible for all commercial activities relating to the Product in Malaysia.
“We are pleased to be collaborating with Pharm-D which has such a good understanding of the antidotes and dye market in Malaysia. Moreover, we are pleased to work together to make Proveblue® 5 mg/ml solution for injection available for Malaysian patients.,” says Michel Feraud, CEO and founder of Provepharm.
“We are delighted to be collaborating with Provepharm with whom we share similar values and goals. This collaboration is in line with Pharm-D’s mission to launch and provide products that respond to medical and patient needs of Malaysia,” says Mr. Lim Kean Ping, CEO of Pharm-D.
Provepharm is an international, private pharmaceutical group, pioneering the 3rd way, based on innovation using mature, well-known molecules for hospital use. Provepharm’s portfolio of products meets the highest pharmaceutical quality standards, in the following areas: antidotes, diagnostics, injectable vitamins, metabolism, and neuroscience. Working closely with healthcare professionals, Provepharm is also committed to develop specific services to improve clinical practices and seize opportunities in Europe and the US, as well as in countries selected for their high potential.
With offices in Marseille (France) and Philadelphia (USA), the group had over 125 employees in 2022, and recorded sales of 77 million euros, 23% of which were devoted to R&D. With over 4.4 million treatments marketed in more than 30 countries, Provepharm intends to generate a positive and significant social, societal and environmental impact through its activities.
About Pharm-D Malaysia
Pharm-D Malaysia is a leading healthcare and pharmaceutical company dedicated to deliver innovative healthcare and medical solutions.
Based in Malaysia and Singapore with a strong presence in the healthcare industry across Southeast Asia, Pharm-D’s comprehensive portfolio encompasses a wide range of pharmaceuticals, including special medicines, nutritional supplements and over-the-counter products.
Dedicated to meet diverse healthcare needs and putting patient’s needs first, Pharm-D has worked with numerous partners and suppliers including agencies with an unsurpassed database linked to an international network that spans over 30,000 medicines. With a patient-centric approach, Pharm-D continues to make significant impacts on improving healthcare quality and patient’s wellbeing.